Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 18 through 70 years at the time of screening~2. Diagnosis of paediatric or adult SLE with a diagnosis of SLE according to the ACR 1982 revised criteria ≥24 weeks prior to signing the Informed Consent form (ICF)~3. Currently receiving at least 1 of the following:~   1. Where prednisone is the single standard of care medication (ie, the subject is not concurrently receiving any medication listed in inclusion criterion 3(c)), a dose of oral prednisone ≥7.5 mg/day but ≤40 mg/day (or prednisone equivalent) for a minimum of 8 weeks prior to Day 1. In addition, the dose of oral prednisone or prednisone equivalent the subject is taking must be stable for a minimum of 2 weeks prior to randomisation~  2. Where prednisone is not the single standard of care medication (ie, the subject is concurrently receiving at least one medication listed in inclusion criterion 3(c), a dose of oral prednisone (≤40 mg/day) (or prednisone equivalent) for a minimum of 2 weeks prior to signing of the ICF. In addition, the dose of oral prednisone or prednisone equivalent the subject is taking must be stable for a minimum of 2 weeks prior to randomisation.~  3. Any of the following medications administered for a minimum of 12 weeks prior to signing the informed consent, and at a stable dose for a minimum of 8 weeks prior to signing the informed consent and through Day 1:~   (i) Azathioprine ≤200 mg/day (ii) Antimalarial (eg, chloroquine, hydroxychloroquine, quinacrine) (iii) Mycophenolate mofetil ≤2 g/day or mycophenolic acid ≤1.44 g/day (iv) Oral, subcutaneous (SC), or intramuscular methotrexate ≤25 mg/week (v) Mizoribine ≤150 mg/day~4. Fulfils at least 4 of the 11 ACR modified 1982 classification criteria for SLE, at least 1 of which must be:~   1. Positive antinuclear antibody (ANA) test at screening by immunofluorescent assay (IFA) at the central laboratory with titre ≥1:80; OR~  2. Anti-dsDNA antibodies at screening elevated to above normal (including indeterminate), as per the central laboratory; OR~  3. Anti-Smith (anti-Sm) antibody at screening elevated to above normal as per the central laboratory~5. At Screening, Disease Activity Adjudication Group confirmation of:~   SLEDAI-2K Criteria: SLEDAI-2K score ≥6 points and Clinical SLEDAI-2K score ≥4 points. The Clinical SLEDAI-2K is the SLEDAI-2K assessment score without the inclusion of points attributable to any urine or laboratory results including immunologic measures.~6. Must not have active or latent TB on either chest radiograph or by quantiferon gold test~7. Day 1 Clinical SLEDAI-2K score ≥4 points~8. OCS dose stable for at least 2 weeks prior to randomisation~9. Stable SLE SOC treatment at the time of randomisation~10. Women of child-bearing potential must have a negative serum β-hCG test at and negative urine pregnancy test at randomisation prior to administration of investigational product~Exclusion Criteria:~1. Receipt of any investigational product (small molecule or biologic agent) within 4 weeks or 5 half-lives prior to signing of the ICF, whichever is greater~2. Receipt of any of the following:~   (a) Intra-articular, intramuscular or IV glucocorticosteroids within 6 weeks prior to Day 1~3. History of, or current diagnosis of, a clinically significant non SLE-related vasculitis syndrome.~4. Active severe or unstable neuropsychiatric SLE~5. Active severe SLE-driven renal disease~6. Diagnosis (within 1 year of signing the ICF) of mixed connective tissue disease or any history of overlap syndromes of SLE or SSc.~7. History of, or current, inflammatory joint or skin disease other than SLE~8. History of any non-SLE disease that has required treatment with oral or parenteral corticosteroids for more than 2 weeks within the last 24 weeks prior to signing the ICF~9. 26.27. Known history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the subject to infection, or a positive result for human immunodeficiency virus (HIV) infection confirmed by central laboratory at screening. Subjects refusing HIV testing during the screening period will not be eligible for study participation~10. Confirmed positive test for hepatitis B or hepatitis C~11. Any severe herpes infection at any time prior to Week 0 (Day 1)~12. Opportunistic infection requiring hospitalisation or intravenous antimicrobial treatment within 3 years prior to randomization~13. History of cancer, apart from:~    1. Squamous or basal cell carcinoma of the skin that has been successfully treated~   2. Cervical cancer in situ that has been successfully treated

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Anifrolumab (Type: EXPERIMENTAL): Anifrolumab 300 mg intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete